Complications of allogeneic hematopoietic stem cell transplantation (Q38217938)

31 August 2017

title

Complications of allogeneic hematopoietic stem cell transplantation (English)

1 reference

31 August 2017

Karim Arnaout

1

1 reference

31 August 2017

Nihar Patel

2

1 reference

31 August 2017

Maneesh Jain

3

1 reference

31 August 2017

Joelle El-Amm

4

1 reference

31 August 2017

Farah Amro

5

1 reference

31 August 2017

Imad A Tabbara

6

1 reference

31 August 2017

publication date

5 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

32

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

349-362

1 reference

Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Allogeneic hematopoietic cell transplantation: the state of the art

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Allogeneic stem cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Myeloablative conditioning regimens for AML allografts: 30 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Acyclovir prophylaxis of herpes-simplex-virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Fiberoptic bronchoscopy in allogeneic bone marrow transplantation: findings in the era of serum cytomegalovirus antigen surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Pulmonary infections after bone marrow transplantation: clinical and radiographic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Risk of cytomegalovirus infection after peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Fungal infections in patients undergoing blood and marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

The clinical spectrum of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Invasive pulmonary aspergillosis: frequency and meaning of the "hypodense sign" on unenhanced CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Acute graft-versus-host disease following hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

A biomarker panel for acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Prophylaxis regimens for GVHD: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Dermatologic treatment of cutaneous graft versus host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Novel treatment concepts for graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Recognizing and managing chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Peripheral-blood stem cells versus bone marrow from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

The pathophysiology of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Many faces of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

How I treat chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Chronic graft-versus-host disease: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Outside-in: peptide versus integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Solid cancers after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

Diagnosis and management of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2014.919301

10.3109/07357907.2014.919301

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference